Financial Consulate Inc. Acquires New Holdings in 10x Genomics $TXG

Financial Consulate Inc. bought a new position in shares of 10x Genomics (NASDAQ:TXG) during the 3rd quarter, according to its most recent 13F filing with the SEC. The firm bought 156,457 shares of the company’s stock, valued at approximately $1,829,000. Financial Consulate Inc. owned 0.13% of 10x Genomics as of its most recent filing with the SEC.

Other institutional investors have also recently bought and sold shares of the company. Allworth Financial LP increased its position in shares of 10x Genomics by 150.4% during the second quarter. Allworth Financial LP now owns 2,271 shares of the company’s stock worth $26,000 after acquiring an additional 1,364 shares in the last quarter. True Wealth Design LLC boosted its stake in 10x Genomics by 1,552.5% in the 2nd quarter. True Wealth Design LLC now owns 3,586 shares of the company’s stock worth $42,000 after purchasing an additional 3,369 shares during the period. Blue Trust Inc. increased its holdings in 10x Genomics by 48.1% during the 2nd quarter. Blue Trust Inc. now owns 4,894 shares of the company’s stock worth $57,000 after purchasing an additional 1,590 shares in the last quarter. EverSource Wealth Advisors LLC increased its holdings in 10x Genomics by 203.9% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 7,490 shares of the company’s stock worth $87,000 after purchasing an additional 5,025 shares in the last quarter. Finally, Quarry LP bought a new position in 10x Genomics during the 1st quarter worth about $78,000. Institutional investors own 84.68% of the company’s stock.

Insider Buying and Selling at 10x Genomics

In other 10x Genomics news, CFO Adam Taich sold 11,888 shares of the company’s stock in a transaction on Monday, November 24th. The shares were sold at an average price of $19.00, for a total value of $225,872.00. Following the transaction, the chief financial officer directly owned 297,385 shares in the company, valued at $5,650,315. The trade was a 3.84% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Serge Saxonov sold 13,261 shares of the firm’s stock in a transaction dated Monday, November 24th. The stock was sold at an average price of $19.00, for a total transaction of $251,959.00. Following the sale, the chief executive officer owned 1,021,556 shares of the company’s stock, valued at approximately $19,409,564. This represents a 1.28% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 33,432 shares of company stock valued at $635,208 in the last quarter. 9.39% of the stock is currently owned by insiders.

10x Genomics Price Performance

Shares of TXG opened at $16.31 on Friday. The company has a market cap of $2.06 billion, a PE ratio of -26.31 and a beta of 2.18. The firm has a 50-day moving average of $16.21 and a 200-day moving average of $13.91. 10x Genomics has a one year low of $6.78 and a one year high of $20.34.

10x Genomics (NASDAQ:TXG) last issued its earnings results on Thursday, November 6th. The company reported ($0.22) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.27) by $0.05. The business had revenue of $149.00 million during the quarter, compared to the consensus estimate of $142.50 million. 10x Genomics had a negative net margin of 11.89% and a negative return on equity of 11.50%. 10x Genomics’s revenue was down 1.7% on a year-over-year basis. During the same period last year, the business posted ($0.30) EPS. Analysts expect that 10x Genomics will post -1.43 earnings per share for the current year.

Analysts Set New Price Targets

TXG has been the topic of a number of research reports. UBS Group boosted their price target on 10x Genomics from $13.00 to $14.00 and gave the company a “neutral” rating in a report on Friday, November 7th. Barclays boosted their target price on 10x Genomics from $17.00 to $22.00 and gave the company an “overweight” rating in a research note on Monday, December 15th. Wall Street Zen cut shares of 10x Genomics from a “buy” rating to a “hold” rating in a research note on Saturday, November 15th. Canaccord Genuity Group boosted their price objective on shares of 10x Genomics from $19.00 to $20.00 and gave the stock a “buy” rating in a research report on Monday, December 22nd. Finally, JPMorgan Chase & Co. increased their target price on shares of 10x Genomics from $13.00 to $15.00 and gave the stock a “neutral” rating in a report on Friday, November 7th. Four equities research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and three have assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $15.81.

10x Genomics Profile

10x Genomics, Inc is a biotechnology company specializing in advanced genomic analysis solutions that enable researchers to explore biology at unprecedented resolution. The company develops and manufactures integrated hardware, consumables and software products for single-cell sequencing and spatial genomics. Its flagship Chromium product line supports applications in single-cell RNA sequencing, immune profiling and genome assembly, while the Visium and Xenium platforms offer spatial transcriptomics and in situ analysis, respectively.

Founded in 2012 and headquartered in Pleasanton, California, 10x Genomics serves a global customer base that includes academic institutions, pharmaceutical and biotechnology companies, and government research organizations.